Area of research
Hepatology · Epidemiology
Research interest
Research focused on Immunology and Hepatocellular carcinoma, with related work in Sofosbuvir, Hepatitis B virus, Entecavir. Notable publications include 'Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians', 'Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis', and 'Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy'.
EASL position paper on clinical follow-up after HCV cure
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C
Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses
Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
Long‐term changes in liver elasticity in hepatitis C virus‐infected patients with sustained virologic response after treatment with direct‐acting antivirals
Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis
Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry
Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy
Direct-Acting Antiviral–Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
Antiviral treatment and liver‐related complications in hepatitis delta
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D
Improvement of liver function parameters in advanced <scp>HCV</scp> ‐associated liver cirrhosis by <scp>IFN</scp> ‐free antiviral therapies
Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients
Long‐term outcome of liver transplant patients with Budd‐Chiari syndrome secondary to myeloproliferative neoplasms